BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36863187)

  • 1. Assessing vaginal wall thickness by transvaginal ultrasound in breast cancer survivors: A pilot study.
    Ros C; Mension E; Rius M; Munmany M; De Guirior C; Espuña-Pons M; Anglès-Acedo S; Castelo-Branco C
    Maturitas; 2023 May; 171():7-12. PubMed ID: 36863187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship Between Genitourinary Syndrome of Menopause and 3D High-Frequency Endovaginal Ultrasound Measurement of Vaginal Wall Thickness.
    Peker H; Gursoy A
    J Sex Med; 2021 Jul; 18(7):1230-1235. PubMed ID: 34193368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyspareunia Related to GSM: Association of Total Vaginal Thickness via Transabdominal Ultrasound.
    Balica AC; Cooper AM; McKevitt MK; Schertz K; Wald-Spielman D; Egan S; Bachmann GA
    J Sex Med; 2019 Dec; 16(12):2038-2042. PubMed ID: 31542351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study.
    Mension E; Alonso I; Cebrecos I; Castrejon N; Tortajada M; Matas I; Gómez S; Ribera L; Anglès-Acedo S; Castelo-Branco C
    Climacteric; 2022 Oct; 25(5):476-482. PubMed ID: 35343852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause: The LIGHT Randomized Clinical Trial.
    Mension E; Alonso I; Anglès-Acedo S; Ros C; Otero J; Villarino Á; Farré R; Saco A; Vega N; Castrejón N; Ordi J; Rakislova N; Tortajada M; Matas I; Gómez S; Ribera L; Castelo-Branco C
    JAMA Netw Open; 2023 Feb; 6(2):e2255697. PubMed ID: 36763359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors.
    Carter J; Baser RE; Goldfrank DJ; Seidel B; Milli L; Stabile C; Canty J; Saban S; Goldfarb S; Dickler MN; Gardner GJ; Jewell EL; Sonoda Y; Kollmeier MA; Alektiar KM
    Support Care Cancer; 2021 Jan; 29(1):311-322. PubMed ID: 32358778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors.
    Zuo SW; Wu H; Shen W
    Menopause; 2018 Jul; 25(7):828-836. PubMed ID: 29533365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the thickness of the vaginal wall and vaginal mucosa in pre-menopausal versus post-menopausal women by transabdominal ultrasound: A feasibility study.
    Balica A; Wald-Spielman D; Schertz K; Egan S; Bachmann G
    Maturitas; 2017 Aug; 102():69-72. PubMed ID: 28610687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
    Cook ED; Iglehart EI; Baum G; Schover LL; Newman LL
    Menopause; 2017 Dec; 24(12):1360-1364. PubMed ID: 28640166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
    The NAMS 2020 GSM Position Statement Editorial Panel
    Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
    Hirschberg AL; Sánchez-Rovira P; Presa-Lorite J; Campos-Delgado M; Gil-Gil M; Lidbrink E; Suárez-Almarza J; Nieto-Magro C
    Menopause; 2020 May; 27(5):526-534. PubMed ID: 32049923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Vaginal Laser Treatment for Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
    Jha S; Wyld L; Krishnaswamy PH
    Clin Breast Cancer; 2019 Aug; 19(4):e556-e562. PubMed ID: 31227415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
    Sussman TA; Kruse ML; Thacker HL; Abraham J
    J Oncol Pract; 2019 Jul; 15(7):363-370. PubMed ID: 31291563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Fractional CO
    Li J; Li H; Zhou Y; Xie M; Miao Y; Wang L; Zhao Y; Ying T; Hu Y; Chen Y; Chen Y; Sun X; Wang J
    Lasers Surg Med; 2021 Jul; 53(5):647-653. PubMed ID: 33211334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health.
    Faubion SS; Larkin LC; Stuenkel CA; Bachmann GA; Chism LA; Kagan R; Kaunitz AM; Krychman ML; Parish SJ; Partridge AH; Pinkerton JV; Rowen TS; Shapiro M; Simon JA; Goldfarb SB; Kingsberg SA
    Menopause; 2018 Jun; 25(6):596-608. PubMed ID: 29762200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study.
    Santos LPA; Bonduki CE; Dardes RCM; Heinke T; Patriarca MT
    Clinics (Sao Paulo); 2022; 77():100116. PubMed ID: 36194923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies.
    Castelo-Branco C; Mension E; Torras I; Cebrecos I; Anglès-Acedo S
    Climacteric; 2023 Aug; 26(4):296-301. PubMed ID: 36946290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
    Comini ACM; Carvalho BM; Moreira MJB; Reis PCA; Colapietro L; Northern J; Batalini F
    Clin Breast Cancer; 2023 Dec; 23(8):835-846. PubMed ID: 37806915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.